Friday's Health Winners & Losers
Health stocks ended the week without fireworks but with continued Vytorin discussions, earnings and regulatory actions -- and interactions.
Merck (MRK) and Schering-Plough (SGP) issued a response on Friday to the criticism of the companies' handling of Vytorin, the Zetia-plus-statin drug that in a clinical trial (called Enhance) showed no advantage to lessening plaque buildup in arteries over a statin alone. The pricier Vytorin, which has been shown to lower cholesterol more so than statins, has been the center of questions as speculation swirls about the reasoning behind the long-delayed release of the Enhance trial data and the implications of the results.
The companies said they strongly object to mischaracterizations about the study. "While the ENHANCE trial was time consuming and took longer than originally anticipated to complete, our companies acted with integrity and good faith in connection with the trial. We took numerous actions to assure the quality of the reading of the ultrasound images," said Thomas Koestler, president of Schering-Plough Research Institute in a release.
The Food and Drug Administration then held a press briefing Friday afternoon, noting that the lowering of LDL cholesterol is a widely accepted measure of the success of lipid-lowering drugs and an accepted endpoint that's the basis for approval for such drugs. The agency said that it doesn't require the reduction cardiovascular risk or stroke in order to approve such drugs, and noted that it wouldn't change its approval process for such drugs at this point.The FDA said it could be late this year before it will be able to complete a review of the study results. And it will remain to be seen until data from another study is available in 2011 whether the reduction in cholesterol translates into reduced risk of adverse cardiovascular events. Watch for more coverage on the FDA briefing and the Merck/Schering data from TheStreet.com writer Melissa Davis. Merck traded down 3.6% to $47.79, and Schering-Plough fell 5.7% to $19.02. Both stocks are components of the Amex pharmaceutical index, which was down 2.2% at 314.21. Cephalon (CEPH) said Friday that the FDA accepted the company's supplemental new-drug application (sNDA) for Fentora for the management of breakthrough pain in opioid-tolerant patients with chronic pain. But the agency notified the Company that it will convene an advisory committee panel on May 6 to consider the application. The FDA often calls a panel of experts to discuss questions or concerns about data or a product in general, and typically takes the panels' recommendation on whether to approve it, although it's not bound to. Shares fell 4.7% to $65.86. Amgen (AMGN) shares were up on Friday, after Thursday postclose the company divulged
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV